Amgen Inc (AMGN): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Amgen ( AMGN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.5%. By the end of trading, Amgen rose $2.95 (2.6%) to $116.43 on average volume. Throughout the day, 3,547,181 shares of Amgen exchanged hands as compared to its average daily volume of 2,961,300 shares. The stock ranged in a price between $113.27-$116.79 after having opened the day at $113.50 as compared to the previous trading day's close of $113.48. Other companies within the Health Care sector that increased today were: Neurocrine Biosciences ( NBIX), up 89.7%, Epizyme ( EPZM), up 75.6%, Pharmacyclics ( PCYC), up 19.8% and Imprimis Pharmaceuticals ( IMMY), up 19.2%.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $86.3 billion and is part of the drugs industry. The company has a P/E ratio of 18.1, above the S&P 500 P/E ratio of 17.7. Shares are down 0.5% year to date as of the close of trading on Monday. Currently there are 8 analysts that rate Amgen a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the negative front, Mast Therapeutics ( MSTX), down 23.6%, BG Medicine ( BGMD), down 9.3%, TetraLogic Pharmaceuticals Corporation ( TLOG), down 6.4% and CytRx Corporation ( CYTR), down 5.3% , were all laggards within the health care sector with Salix Pharmaceuticals ( SLXP) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback